Mkts

Aktis Oncology, Inc.

NASDAQ: AKTS
$16.31+0.15 (+0.93%)
As of Nov 17, 4:00 PM ET

Key statistics

Day range
15.6016.46
52-week range
13.9634.19
Today
Open15.96
Previous close16.31
Volume283.0K
Valuation
Market cap907.15M
P/E ratio—
EPS (TTM)-2.07
Income & risk
Dividend / yield—
Beta206.60
Avg volume366.6K
Discussion

AKTS News

Stories mentioning AKTS from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q1 '25Mar 31
Income Statement
Revenue3,2271,447
Cost of Goods Sold
Gross Profit
Operating Expenses
Research & Development20,03615,863
Sales General & Admin
Total Operating Expenses25,93319,590
Operating Income (Loss)(22,706)(18,143)
Interest Income4,3843,171
Interest Expense
Other Expense(3.00)(13.00)
Pretax Income
Tax Provision
Net Income (Loss)(18,325)(14,985)
Earnings Per Share (Basic)(0.38)(18.60)
Earnings Per Share (Diluted)(0.38)(18.60)
Weighted Average Shares Outstanding (Basic)48,630806.00
Weighted Average Shares Outstanding (Diluted)48,630806.00

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About AKTS

Aktis Oncology, Inc. (NASDAQ: AKTS) is a stock listed on the Nasdaq Stock Market under the ticker symbol AKTS. It last traded at $16.31 (Nov 17, 2026, 4:00 PM ET), up 0.9% on the day. That gives Aktis Oncology a market capitalisation of $907.2M.

Over the past 52 weeks AKTS has traded between $13.96 and $34.19.

Revenue for the quarter ended Mar 31, 2026 was $3.2M; a net loss of $18.3M. Revenue was up 123% from $1.4M in the quarter ended Mar 31, 2025.

Last 2 quarters
Quarter endedRevenueNet incomeMargin
Mar 31, 2026$3.2M-$18.3M-567.9%
Mar 31, 2025$1.4M-$15.0M-1035.6%

From Aktis Oncology’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…